Evelyn M.l. Loo, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
James Duran Mendez, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Meheret M. Asgedom, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Augustine C. Mekkam, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Emily Jessie Chen, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 310-907-8899 |
Samina Agha, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Hong-zhuan Tang, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Carol Min, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Laura Elizabeth Gannaway, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
Julie S. Zhang, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 901 Nevin Ave, Richmond, CA 94801 Phone: 510-307-1500 |
News Archive
The Contra Costa Times: "The effort to overhaul the nation's health care system has so far skirted the issue of tort reform, intensifying debate over the role malpractice lawsuits play in increasing premiums." Critics say the new health reform law does not do enough to address the high costs of medical lawsuits, but other experts say that malpractice suits do not contribute to increasing health costs.
NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
Addiction is on the rise in Europe. An increasing number of young people are unable to control their use of drugs, alcohol, sex, computer games, technology, shopping, dieting or exercise.
› Verified 7 days ago